IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

Avacta Group PLC - AIM-listed developer of Affimer biotherapeutics and reagents - Enters ...

Alliance News 6 April, 2021 | 1:53PM
Email Form Facebook Twitter LinkedIn RSS

Avacta Group PLC - AIM-listed developer of Affimer biotherapeutics and reagents - Enters distribution agreement with Abcam PLC to sell its recently developed SARS-CoV-2 research Elisa Affimer reagents.

Under the global, non-exclusive distribution agreement, Abcam will enable the global research community to access Avacta's SARS-CoV-2 spike protein Affimer research reagents through its online catalogue.

"This will allow scientists around the world to perform the Elisa test in their own laboratories and support the global fight against the pandemic," says Avacta.

Current Avacta stock price: 248.05 pence, up 6.5% on Tuesday

Year-to-date change: more than double 114p at end of 2020

Current Abcam stock price: 1,396.50p, down 1.0% on Tuesday

Year-to-date change: down 10%

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Avacta Group PLC 118.40 -
Abcam PLC 1,647.00 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.